QuoNova

QuoNova is a biotechnology company dedicated to developing next-generation oral small molecule therapies for metabolic diseases, with a primary focus on obesity and type 2 diabetes. Founded by a team of experienced drug hunters from Pfizer, the company leverages deep expertise in G protein-coupled receptor (GPCR) biology to create potent and selective GLP-1 receptor agonists. QuoNova's lead programs aim to provide the efficacy of injectable biologics in a more convenient oral format, addressing significant unmet needs in the cardiometabolic space. The company is backed by leading life science investors including Atlas Venture and Access Biotechnology. By focusing on oral bioavailability and optimized pharmacology, QuoNova seeks to expand patient access to transformative metabolic treatments.